[go: up one dir, main page]

MX2021010761A - Compounds and compositions for modulating egfr mutant kinase activities. - Google Patents

Compounds and compositions for modulating egfr mutant kinase activities.

Info

Publication number
MX2021010761A
MX2021010761A MX2021010761A MX2021010761A MX2021010761A MX 2021010761 A MX2021010761 A MX 2021010761A MX 2021010761 A MX2021010761 A MX 2021010761A MX 2021010761 A MX2021010761 A MX 2021010761A MX 2021010761 A MX2021010761 A MX 2021010761A
Authority
MX
Mexico
Prior art keywords
provides
protein kinase
present
compositions
compounds
Prior art date
Application number
MX2021010761A
Other languages
Spanish (es)
Inventor
Jaekyoo Lee
Jong Sung Koh
In Yong Lee
Jaesang Lee
Paresh Devidas Salgaonkar
Dong Sik Jung
Byung-Chul Suh
Ho-Juhn Song
Jung-Ho Kim
Se-Won Kim
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55654993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021010761(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of MX2021010761A publication Critical patent/MX2021010761A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quick-Acting Or Multi-Walled Pipe Joints (AREA)

Abstract

The present invention provides a new group of protein kinase inhibitors, aminopyrimidine derivatives, and pharmaceutically acceptable salts thereof that are useful for treating cell proliferative disease and disorder such as cancer and immune disease. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefore. The invention also provides useful intermediates generated during the syntheses of the aminopyrimidine derivatives.
MX2021010761A 2014-10-13 2017-03-10 Compounds and compositions for modulating egfr mutant kinase activities. MX2021010761A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462063394P 2014-10-13 2014-10-13

Publications (1)

Publication Number Publication Date
MX2021010761A true MX2021010761A (en) 2022-06-09

Family

ID=55654993

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017003181A MX2017003181A (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities.
MX2020002168A MX385942B (en) 2014-10-13 2015-10-13 COMPOUNDS AND COMPOSITIONS FOR MODULATING EPIDERMAL GROWTH FACTOR RECEPTOR MUTANT KINASE ACTIVITIES.
MX2021010761A MX2021010761A (en) 2014-10-13 2017-03-10 Compounds and compositions for modulating egfr mutant kinase activities.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2017003181A MX2017003181A (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities.
MX2020002168A MX385942B (en) 2014-10-13 2015-10-13 COMPOUNDS AND COMPOSITIONS FOR MODULATING EPIDERMAL GROWTH FACTOR RECEPTOR MUTANT KINASE ACTIVITIES.

Country Status (30)

Country Link
US (2) US9593098B2 (en)
EP (4) EP3207035B1 (en)
JP (3) JP6524221B2 (en)
KR (5) KR20240074820A (en)
CN (2) CN111686110B (en)
AU (1) AU2015331166B2 (en)
BR (1) BR112017007769B1 (en)
CA (1) CA2962914C (en)
CY (2) CY1122737T1 (en)
DK (4) DK3929190T3 (en)
ES (3) ES3009926T3 (en)
FI (3) FI4421069T3 (en)
FR (1) FR25C1021I2 (en)
HR (3) HRP20250213T1 (en)
HU (4) HUE048006T2 (en)
LT (5) LT3929190T (en)
MX (3) MX2017003181A (en)
NL (1) NL301329I2 (en)
NO (1) NO2025025I1 (en)
NZ (1) NZ730012A (en)
PH (1) PH12017500488A1 (en)
PL (3) PL3604294T3 (en)
PT (4) PT3929190T (en)
RS (3) RS66529B1 (en)
RU (1) RU2727700C2 (en)
SG (1) SG11201701960XA (en)
SI (3) SI3604294T1 (en)
SM (3) SMT202000059T1 (en)
TW (2) TWI730331B (en)
WO (1) WO2016060443A2 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3929190T (en) * 2014-10-13 2025-02-19 Yuhan Corp Compounds and compositions for modulating egfr mutant kinase activities
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
JP2019501222A (en) 2016-01-07 2019-01-17 シーエス ファーマテック リミテッド Selective inhibitors of clinically important variants of EGFR tyrosine kinase
JP7030066B2 (en) * 2016-05-26 2022-03-04 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー EGFR inhibitor compound
KR102030886B1 (en) * 2016-09-23 2019-10-10 재단법인 대구경북첨단의료산업진흥재단 Novel imidazolyl pyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient
AR111469A1 (en) 2017-04-21 2019-07-17 Yuhan Corp COME OUT OF AN AMINOPIRIDINE DERIVATIVE COMPOUND, A CRYSTAL FORM OF THE SAME, AND A PROCESS TO PREPARE THE SAME
JP7028900B2 (en) * 2017-06-13 2022-03-02 ベイジン アダマドル バイオテクノロジー リミテッド ライアビリティ カンパニー Aminopyrimidine compounds, their preparation methods, and their use
MX2022008743A (en) * 2017-07-28 2023-02-02 Yuhan Corp Improved process for preparing aminopyrimidine derivatives.
MA49703A (en) * 2017-07-28 2021-04-21 Yuhan Corp NEW USEFUL INTERMEDIARIES FOR THE SYNTHESIS OF AMINOPYRIMIDINE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PROCESS FOR THE PREPARATION OF AMINOPYRIMIDINE DERIVATIVES USING THEM
DK3658547T3 (en) * 2017-07-28 2023-10-16 Yuhan Corp PROCESS FOR THE PREPARATION OF N-(5-(4-(4-FORMYL-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YLAMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE
CN111518082B (en) * 2017-08-30 2021-09-17 深圳市塔吉瑞生物医药有限公司 Aminopyrimidine compound, composition containing aminopyrimidine compound and application of aminopyrimidine compound
CN108017633A (en) * 2018-01-30 2018-05-11 天津大学 N- [5- (pyrimidine -2- amino) -2,4- di-substituted-phenyls] -2- fluoropropenes amide derivatives and application
CN108047207A (en) * 2018-01-30 2018-05-18 天津大学 N- [5- (pyrimidine -2- amino) -2,4- di-substituted-phenyls] the deuterated objects of -2- fluoropropenes amides and application
US12336995B2 (en) 2018-09-10 2025-06-24 Mirati Therapeutics, Inc. Combination therapies
KR20200043618A (en) * 2018-10-18 2020-04-28 주식회사유한양행 Pharmaceutical composition for oral administration comprising an aminopyrimidine derivative or its salt
WO2020125391A1 (en) * 2018-12-21 2020-06-25 深圳市塔吉瑞生物医药有限公司 Aminopyrimidine compound used for inhibiting activity of protein kinase
CA3131654A1 (en) 2019-02-26 2020-09-03 Janssen Biotech, Inc. Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
HUE073283T2 (en) * 2019-03-19 2026-01-28 Voronoi Inc Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
CN111747950B (en) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 Pyrimidine derivatives for the treatment of cancer
US12465608B2 (en) 2019-03-29 2025-11-11 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer
BR112021022828A2 (en) * 2019-05-14 2022-04-12 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and third-generation egfr tyrosine kinase inhibitors
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
MY208668A (en) 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
CN110128354A (en) * 2019-06-20 2019-08-16 大连大学 A kind of preparation method of 5-fluoro-2-methylsulfonyl-4-aminopyrimidine
KR20210032093A (en) 2019-09-16 2021-03-24 제이투에이치바이오텍 (주) Pyrimidine derivatives showing growth inhibition of EGFR mutation kinase and medical use thereof
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
MX2022008874A (en) 2020-01-20 2022-08-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer.
JOP20220184A1 (en) 2020-02-12 2023-01-30 Janssen Biotech Inc TREATMENT OF PATIENTS HAVING c-MET EXON 14 SKIPPING MUTATIONS
TW202207940A (en) 2020-04-14 2022-03-01 美商健生生物科技公司 Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
KR20210152312A (en) * 2020-06-08 2021-12-15 주식회사 종근당 4-(4,5-dihydro-1h-pyrazol-1-yl)pyrimidine compound as cannabinoid receptor (cb1 receptor) antagonists and pharmaceutical composition including the same
US20230321087A1 (en) 2020-09-14 2023-10-12 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies
TWI867047B (en) * 2020-09-18 2024-12-21 南韓商沃若諾伊公司 Heteroaryl derivatives, method of preparing same, and pharmaceutical composition including same as active ingredient
TW202227425A (en) * 2020-09-18 2022-07-16 南韓商沃若諾伊生物公司 Heteroaryl derivatives, preparation method for the same, and a pharmaceutical composition comprising the same as an active ingredient
KR20220085735A (en) * 2020-12-14 2022-06-22 보로노이바이오 주식회사 Isoxazolidine derivative compounds, and uses thereof
CN117255792A (en) * 2021-05-07 2023-12-19 沃若诺伊公司 Heteroaryl derivatives, process for preparing the same and pharmaceutical compositions comprising the same as active ingredient
JP2024519626A (en) 2021-05-17 2024-05-21 ボロノイ インコーポレイテッド Heteroaryl derivative compounds and uses thereof
CN117425651A (en) 2021-06-01 2024-01-19 杭州领业医药科技有限公司 Hydrate crystal form of Lazertinib mesylate and its preparation method and use
KR102685187B1 (en) 2021-10-15 2024-07-16 제이투에이치바이오텍 (주) Compounds inhibiting ALK and/or EGFR mutation kinases and medical use thereof
TW202342057A (en) 2022-02-07 2023-11-01 美商健生生物科技公司 Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
US20250205233A1 (en) 2022-03-31 2025-06-26 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
JP2025516171A (en) 2022-04-28 2025-05-27 アストラゼネカ・アクチエボラーグ Fused bicyclic heteroaromatic compounds and their use in the treatment of cancer - Patents.com
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
MA71241A (en) 2022-06-27 2025-04-30 Astrazeneca Ab COMBINATIONS INVOLVING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
KR20250044679A (en) 2022-07-08 2025-04-01 아스트라제네카 아베 Epidermal growth factor receptor tyrosine kinase inhibitors in combination with HGF-receptor inhibitors for cancer treatment
AU2023371904A1 (en) * 2022-11-03 2025-04-17 Voronoi Inc. Fumarate, tartrate, malate, and citrate salts of an egfr inhibitor
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
CN116655600B (en) * 2023-05-23 2025-08-22 江南大学 A substituted 2-arylaminopyrimidine compound, pharmaceutical composition and use thereof
WO2025017409A1 (en) 2023-07-14 2025-01-23 Janssen Biotech, Inc. Dosing regimen for therapies comprising bispecific antiegfr/c-met antibodies
WO2025052273A1 (en) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer
WO2026009146A1 (en) 2024-07-01 2026-01-08 Hetero Labs Limited Benzimidazole compounds as egfr inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9815453A (en) 1997-03-11 2001-10-23 Du Pont Compound, herbicidal composition and method for controlling the growth of unwanted vegetation
AU2001237041B9 (en) * 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
WO2002059111A2 (en) 2000-12-21 2002-08-01 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
PL369259A1 (en) 2001-11-01 2005-04-18 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
PL377795A1 (en) * 2002-11-28 2006-02-20 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
JP4428565B2 (en) 2004-10-05 2010-03-10 東京エレクトロン株式会社 Treatment liquid application equipment
JP2008515986A (en) 2004-10-13 2008-05-15 ワイス N-benzenesulfonyl substituted anilino-pyrimidine analogues
JP5208516B2 (en) 2004-12-30 2013-06-12 エグゼリクシス， インコーポレイテッド Pyrimidine derivatives as kinase modulators and methods of use
US20070072894A1 (en) 2005-03-24 2007-03-29 Kempf J V Synthesis of pyrroloquinoline quinone (PQQ)
JP5007029B2 (en) 2005-07-13 2012-08-22 Ｎｔｎ株式会社 Grease composition and rolling bearing with grease
EP1919470A1 (en) 2005-08-25 2008-05-14 F.Hoffmann-La Roche Ag FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS
JP2007117465A (en) 2005-10-28 2007-05-17 Sharp Corp Dust collector and vacuum cleaner provided with the same
GB2450046B (en) 2006-03-29 2011-03-09 Kt Freetel Co Ltd Digital device and method for providing additional service by using the same
JP5255559B2 (en) 2006-03-31 2013-08-07 アボット・ラボラトリーズ Indazole compound
EP2004638A1 (en) 2006-04-12 2008-12-24 Wyeth a Corporation of the State of Delaware Anilino-pyrimidine phenyl and benzothiophene analogs
WO2008079291A2 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
MX382352B (en) * 2008-06-27 2025-03-13 Celgene Car Llc HETEROARYL COMPOUNDS AND THEIR USES.
ES2659725T3 (en) 2009-05-05 2018-03-19 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and disorder treatment procedure
NZ599041A (en) * 2009-11-13 2014-05-30 Genosco Kinase inhibitors
MX337477B (en) 2011-02-25 2016-03-07 Yuhan Corp Diaminopyrimidine derivatives and processes for the preparation thereof.
LT3333161T (en) * 2011-07-27 2020-05-11 Astrazeneca Ab 2- (2,4,5-SUBSTITUTED-ANILINE) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USED IN THE TREATMENT OF CANCER
ES2668479T3 (en) * 2012-01-20 2018-05-18 Genosco Substituted pyrimidine compounds and their use as SYK inhibitors
WO2014040555A1 (en) * 2012-09-12 2014-03-20 山东亨利医药科技有限责任公司 Nitrogen-containing heteroaromatic ring derivative as tyrosine kinase inhibitor
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
EP3036231B1 (en) * 2013-08-22 2020-02-26 Jubilant Biosys Ltd. Substituted pyrimidine compounds, compositions and medicinal applications thereof
WO2015094803A1 (en) 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CN104860941B (en) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4-disubstituted phenyl-1,5-diamine derivatives and use thereof, and pharmaceutical composition and medicinal composition prepared from 2,4-disubstituted phenyl-1,5-diamine derivative
CN111875585B (en) 2014-06-12 2023-06-23 上海艾力斯医药科技股份有限公司 A class of kinase inhibitors
HRP20190407T1 (en) 2014-06-19 2019-05-03 Ariad Pharmaceuticals, Inc. HETEROaryl Compounds for Inhibition of Kinases
PT3929190T (en) * 2014-10-13 2025-02-19 Yuhan Corp Compounds and compositions for modulating egfr mutant kinase activities
CN104788427B (en) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3 (2 pyrimdinyl-amino) phenylacryloyl amine compounds and its application

Also Published As

Publication number Publication date
HUE054848T2 (en) 2021-09-28
SMT202100266T1 (en) 2021-07-12
DK3929190T3 (en) 2025-02-24
KR20210011068A (en) 2021-01-29
JP2019163277A (en) 2019-09-26
WO2016060443A2 (en) 2016-04-21
AU2015331166A1 (en) 2017-03-30
US20160102076A1 (en) 2016-04-14
HUE048006T2 (en) 2020-05-28
RS59900B1 (en) 2020-03-31
PL3207035T3 (en) 2020-06-01
NZ730012A (en) 2019-06-28
FR25C1021I1 (en) 2025-08-01
BR112017007769B1 (en) 2023-10-10
HRP20200201T1 (en) 2020-05-15
MX2020002168A (en) 2021-09-07
PT4421069T (en) 2026-01-12
JP6754864B2 (en) 2020-09-16
MX385942B (en) 2025-03-18
ES2770058T3 (en) 2020-06-30
CA2962914A1 (en) 2016-04-21
PT3929190T (en) 2025-02-19
EP3604294A1 (en) 2020-02-05
FR25C1021I2 (en) 2026-02-06
SMT202500069T1 (en) 2025-03-12
AU2015331166B2 (en) 2018-04-26
KR102662358B1 (en) 2024-04-30
KR102487451B1 (en) 2023-01-11
FIC20250023I1 (en) 2025-06-06
FI4421069T3 (en) 2026-01-21
RU2017116598A (en) 2018-11-21
ES2879474T3 (en) 2021-11-22
RS66529B1 (en) 2025-03-31
RS61865B1 (en) 2021-06-30
CY1124359T1 (en) 2022-07-22
LT3929190T (en) 2025-02-25
TWI730331B (en) 2021-06-11
PT3604294T (en) 2021-07-29
EP3604294B1 (en) 2021-05-05
CN111686110A (en) 2020-09-22
PL3929190T3 (en) 2025-06-09
TWI664173B (en) 2019-07-01
EP3929190A1 (en) 2021-12-29
CN106795144B (en) 2020-06-16
LTPA2025522I1 (en) 2025-06-25
BR112017007769A2 (en) 2018-01-16
DK4421069T3 (en) 2026-01-19
SI3929190T1 (en) 2025-04-30
KR20230010836A (en) 2023-01-19
CY1122737T1 (en) 2021-03-12
SG11201701960XA (en) 2017-04-27
HRP20210949T1 (en) 2021-09-03
WO2016060443A3 (en) 2016-06-23
SI3207035T1 (en) 2020-04-30
CN111686110B (en) 2023-06-16
EP3207035A2 (en) 2017-08-23
HUS2500023I1 (en) 2025-06-28
JP2017530999A (en) 2017-10-19
KR20170066650A (en) 2017-06-14
HUE070874T2 (en) 2025-07-28
SI3604294T1 (en) 2021-08-31
ES3009926T3 (en) 2025-03-31
EP4421069A1 (en) 2024-08-28
NO2025025I1 (en) 2025-06-05
DK3604294T3 (en) 2021-06-28
CN106795144A (en) 2017-05-31
RU2020123547A (en) 2020-08-18
EP4421069B1 (en) 2025-12-10
JP2020196740A (en) 2020-12-10
KR102073854B1 (en) 2020-02-05
FI3929190T3 (en) 2025-02-28
KR102208775B1 (en) 2021-01-28
SMT202000059T1 (en) 2020-03-13
JP6524221B2 (en) 2019-06-05
CA2962914C (en) 2018-10-23
EP3207035B1 (en) 2019-11-20
TW201938553A (en) 2019-10-01
EP3207035A4 (en) 2018-03-14
HRP20250213T1 (en) 2025-04-25
EP3929190B1 (en) 2024-12-25
USRE50528E1 (en) 2025-08-12
MX2017003181A (en) 2017-07-20
KR20200014944A (en) 2020-02-11
LT3604294T (en) 2021-07-26
RU2017116598A3 (en) 2018-11-21
DK3207035T3 (en) 2020-01-27
TW201619150A (en) 2016-06-01
LT3207035T (en) 2020-02-25
RU2727700C2 (en) 2020-07-23
PL3604294T3 (en) 2021-11-02
PH12017500488A1 (en) 2017-07-31
LT4421069T (en) 2026-02-10
KR20240074820A (en) 2024-05-28
US9593098B2 (en) 2017-03-14
NL301329I2 (en) 2025-09-09
PT3207035T (en) 2020-02-19

Similar Documents

Publication Publication Date Title
PH12017500488A1 (en) Compounds and compositions for modulating egfr mutant kinase activities
ZA202202097B (en) Amino pyrimidine ssao inhibitors
CY1121433T1 (en) PRODUCTS OF BICYCLE HETEROCYCLES AS INHIBITORS IRAK4
PH12017500196A1 (en) Cyclohexyl-ethyl substituted diaza - and triaza-tricyclic compounds as indole-amine-2, 3-dioxygenase (ido) antagonists for the treatment of cancer
MX2019009501A (en) Amino pyrimidine compounds useful as ssao inhibitors.
PH12016502453B1 (en) Heteroaryl compounds for kinase inhibition
EA201991884A3 (en) G12C KRAS INHIBITORS
EA201792214A1 (en) COMPOUNDS OF SUBSTITUTE QUINAZOLINE
MX2020012165A (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer.
EA033689B9 (en) Inhibitors of kras g12c
MY160820A (en) Kinase inhibitors
MY190835A (en) Bicyclic heterrocyclic derivatives as bromodomain inhibitors
MA39986A (en) Purine derivatives as cd73 inhibitors for the treatment of cancer
MX2013013294A (en) Tyrosine kinase inhibitors.
EA201790921A1 (en) SUBSTITUTED DERIVATIVES OF 2-ANILINPYRIMIDIN AS EGFR MODULATORS
WO2014125408A3 (en) Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
HK1251567A1 (en) Heteroaryl compounds for kinase inhibition
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof
NZ763986A (en) Heteroaryl compounds for kinase inhibition
JOP20160150B1 (en) Substituted quinazoline compounds and methods of use thereof